BREGAL-MILESTONE
15.5.2024 06:01:36 CEST | Business Wire | Press release
Bregal Milestone, a leading European technology and software private equity firm, is pleased to announce the acquisition of Aktieinvest Incentives by its portfolio company, Allshares, a pioneering compensation and long-term incentive software and services provider. Following Allshares’ recent acquisition of Novare Pay, the strategic addition of Aktieinvest Incentives further establishes the company at the forefront of providing comprehensive compensation and incentive solutions in Sweden.
Aktieinvest Incentives is a leading provider of share plan and equity incentive administration to business customers in Sweden. Following the acquisition, Aktieinvest Incentives will fully integrate with Allshares’ state-of-the-art equity plan administration platform. Current Aktieinvest Incentives customers can expect uninterrupted service and will benefit from Allshares’ exceptional client support and end-to-end solutions, including expanded offerings like tax services and IFRS reporting.
In a statement from Louise Hagsten, CEO of Aktieinvest Incentives, the decision to integrate with Allshares was underscored by its unmatched holistic software and services offering. "Our partnership with Allshares heralds a new era of innovation and client-centricity for Aktieinvest Incentives customers. We were drawn to Allshares' commitment to excellence and their robust equity plan administration product suite which includes tax and IFRS reporting capabilities. We are confident that joining forces with Allshares will translate to an enhanced digital participant experience for Aktieinvest Incentives’ customers."
Erika Andersson, former CEO of Novare Pay and recently appointed CEO of Allshares Sweden, stated, “The reception of Allshares by Novare Pay customers and the broader Swedish market has been overwhelmingly positive. I am confident that Aktieinvest Incentives’ customers will have a similar experience, thanks to Allshares’ customer-centric and innovative approach to compensation solutions. The Allshares proposition stands out in the market, and I am eager to maintain our longstanding relationship with Aktieinvest Incentives’ customers. With Allshares, we can offer an enhanced equity plan administration proposition, further improving our ability to serve customers effectively.”
Pertti Helaniemi, CEO of Allshares Finland, highlighted the continuity and seamless experience that customers can expect from the addition of Aktieinvest Incentives to the Allshares ecosystem. "At Allshares, we are dedicated to maintaining high standards of service and innovation. In addition to Allshares’ comprehensive equity plan administration platform, our Pay Incentives, Pay Governance and Pay Analytics service offerings mean clients can expect a seamless one-stop experience for all their compensation needs."
John Hales, Managing Director at Bregal Milestone, reiterated the company's vision and the integral role that Aktieinvest Incentives plays in achieving it. "At Allshares, the vision is to deliver leading compensation solutions that drive high performance for both private and publicly listed customers throughout Europe. The acquisition of Aktieinvest Incentives is a testament to our commitment to this vision, as it strengthens our position as a leader in the Nordic region and reinforces our ability to deliver exceptional value to leading companies. We are thrilled to welcome Aktieinvest Incentives to the Allshares family and look forward to leveraging our combined strengths to deliver distinctive compensation solutions."
Terms of the transaction were not disclosed and are subject to customary closing conditions.
About Bregal Milestone
Bregal Milestone is a leading European software and technology private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €18 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2023. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Allshares
Allshares is a pioneering provider of compensation and incentive solutions in Europe. Trusted by leading multinational enterprises, Allshares will now serve approximately 900 clients in more than 60 countries with an end-to-end digital turnkey solution for equity plan management. Companies and participants can use its proprietary software and services to administer share plans in full compliance with relevant regulations, legal, and tax frameworks, as well as deliver seamless and automated IFRS reporting of share plans to companies. For more information, visit www.allshares.com.
About Aktieinvest
Aktieinvest Incentives is a part of Aktieinvest. Aktieinvest, among Sweden's oldest online brokers, boasts a 50-year legacy and 60,000 customers. Aktieinvest offers monthly share savings, dividend reinvestment, and handles corporate events, essentially simplifying stock investment. With a workforce of around 40, and a customer-centric approach, Aktieinvest has consistently sought to modernize and enhance its offerings, ensuring that clients can seamlessly save and invest in both Swedish and foreign stocks, funds, and ETFs. Since June 2023, Aktieinvest has been under the ownership of Söderberg & Partners, a prominent financial advisor and intermediary in the Nordic region. For more information, visit www.allshares.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514298200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom